AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune ...

AstraZeneca is extending its work with Immunai through a multiyear collaboration that aims to implement its ...

Under the terms of the agreement, AstraZeneca will leverage Immunai’s platform and machine learning capabilities to inform ...

Immunai already has strategic agreements with 30 pharmaceuticals companies, most of them involving much smaller financial ...

(Reuters) - AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune system to make certain cancer drug trials more efficient ...

AstraZeneca in AI Collaboration With Immunai to Inform Cancer Drug Trials (Reuters) - AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model ...